Uncategorised - RNCE

Registre National des Cancers de l’Enfant

5-year overall survival rates of childhood cancer in mainland France, by diagnostic groups and periods

             
               
               

Diagnostic groups and subgroups

2000-2004

2005-2009

2010-2016

p

I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases

83.0

[81.4-84.4]

87.0

[85.6-88.3]

87.6

[86.4-88.7]

**

I.a Lymphoid leukemias

89.2

[87.7-90.5]

91.0

[89.6-92.2]

89.9

[88.6-91.0]

 

I.b Acute myeloid leukemias

59.4

[54.3-64.1]

71.4

[66.2-76.0]

78.2

[74.2-81.7]

**

II. Lymphomas and reticuloendothelial neoplasms

93.6

[91.8-94.9]

93.2

[91.4-94.7]

95.8

[94.6-96.8]

*

II.a Hodgkin lymphomas

96.7

[94.5-98.0]

96.7

[94.4-98.1]

99.3

[98.2-99.7]

**

II.b Non-Hodgkin lymphomas (except Burkitt lymphomas)

91.2

[87.3-93.9]

86.6

[82.1-90.1]

90.5

[87.0-93.2]

 

II.c Burkitt lymphomas

91.4

[87.3-94.3]

95.2

[91.4-97.3]

95.4

[92.3-97.3]

 

III. CNS and miscellaneous intracranial and intraspinal neoplasms

71.1

[69.1-73.0]

74.7

[72.8-76.5]

76.5

[75.0-78.0]

**

III.a Ependymomas and choroid plexus tumors

62.5

[55.3-68.9]

77.6

[71.2-82.8]

80.8

[75.3-85.1]

**

III.b Astrocytomas

86.9

[84.4-89.1]

88.1

[85.5-90.2]

86.4

[84.3-88.2]

 

III.c Intracranial and intraspinal embryonal tumors

52.2

[47.3-56.9]

55.4

[50.4-60.1]

59.0

[54.6-63.1]

 

III.d Other gliomas

35.8

[30.2-41.5]

39.5

[34.0-44.9]

40.2

[35.4-45.0]

 

III.e Other specified intracranial and intraspinal neoplasms

93.8

[90.6-95.9]

95.8

[93.3-97.4]

95.7

[93.7-97.1]

 

IV. Neuroblastomas and other peripheral nervous cell tumors

72.7

[69.3-75.8]

75.3

[72.0-78.3]

80.3

[77.5-82.9]

**

IV.a Neuroblastomas and ganglioneuroblastomas

72.5

[69.1-75.7]

75.2

[71.8-78.2]

80.1

[77.2-82.7]

**

V. Retinoblastomas

99.2

[96.8-99.8]

98.5

[96.0-99.4]

100.0

-

 

VI. Renal tumors

91.6

[88.7-93.7]

92.9

[90.3-94.9]

93.3

[91.0-95.0]

 

VI.a Nephroblastomas and other nonepithelial renal tumors

92.0

[89.1-94.2]

92.9

[90.3-94.9]

93.7

[91.4-95.4]

 

VII. Hepatic tumors

83.1

[72.2-90.0]

78.3

[68.7-85.3]

87.0

[79.8-91.7]

 

VII.a Hepatoblastomas

86.9

[75.5-93.2]

82.0

[71.6-88.9]

87.1

[79.5-92.0]

 

VIII. Malignant bone tumors

74.6

[70.0-78.5]

75.2

[70.7-79.1]

73.1

[68.9-76.8]

 

VIII.a Osteosarcomas

73.1

[66.3-78.7]

74.1

[66.9-79.9]

68.0

[61.5-73.6]

 

VIII.c Ewing tumors and related bone sarcomas

74.7

[67.4-80.6]

74.1

[67.4-79.7]

77.0

[71.1-81.9]

 

IX. Soft tissue and other extraosseous sarcomas

69.0

[64.8-72.7]

73.5

[69.7-77.0]

74.8

[71.4-77.8]

 

IX.a Rhabdomyosarcomas

67.4

[61.6-72.4]

74.3

[69.0-78.8]

76.6

[71.9-80.5]

 

IX.b Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms

74.4

[57.6-85.3]

80.0

[64.0-89.5]

87.9

[76.1-94.0]

 

IX.d Other specified soft tissue sarcomas

72.1

[64.6-78.3]

71.3

[63.9-77.4]

69.6

[62.9-75.2]

 

IX.e Unspecified soft tissue sarcomas

60.0

[43.2-73.3]

70.7

[54.3-82.2]

70.3

[56.4-80.5]

 

X. Germ-cell tumors, trophoblastic tumors, and neoplasms of gonads

92.3

[88.9-94.7]

93.1

[89.8-95.3]

96.5

[94.3-97.9]

 

X.a Intracranial and intraspinal germ cell tumors

91.8

[85.3-95.5]

94.0

[87.9-97.1]

96.5

[92.4-98.4]

 

X.b Malignant extracranial and extragonadal germ cell tumors

92.2

[84.4-96.2]

85.1

[76.2-90.9]

95.3

[89.1-98.0]

*

X.c Malignant gonadal germ cell tumors

95.7

[90.0-98.2]

98.3

[93.2-99.6]

99.2

[94.7-99.9]

 

XI. Other malignant epithelial neoplasms and malignant melanomas

92.8

[89-95.4]

93.3

[89.6-95.7]

93.3

[90.5-95.4]

 

XI.b Thyroid carcinomas

98.2

[93.0-99.5]

100.0

-

98.5

[93.9-99.6]

 

XI.d Malignant melanomas

84.1

[71.6-91.4]

87.2

[73.6-94.0]

90.2

[80.3-95.3]

 

XII. Other and unspecified malignant neoplasms

57.1

[28.4-78.0]

90.0

[65.6-97.4]

81.8

[63.9-91.4]

 

All cancers (excluding Langherhans cell histiocytosis)

80.8

[79.9-81.6]

83.3

[82.5-84.1]

84.6

[83.9-85.2]

**

Langherhans cell histiocytosis

94.3

[79.0-98.5]

97.1

[80.9-99.6]

89.1

[75.7-95.3]

 

All cancers (including Langherhans cell histiocytosis)

80.8

[80.0-81.7]

83.3

[82.5-84.1]

84.6

[83.9-85.3]

**

               

** pvalue <0.01; * pvalue < 0.05

             
               
               

5-year overall survival rates of childhood cancer in mainland France over 2000-2016, by diagnostic and age groups.

                 
                   
 

< 1 year

1-4 years

5-9 years

10-14 years

 

Diagnostic groups and subgroups

I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases

61.2

[56.6-65.5]

89.9

[88.8-90.8]

89.2

[87.9-90.4]

80.8

[78.8-82.5]

**

I.a Lymphoid leukemias

53.8

[46.4-60.7]

93.8

[92.9-94.6]

91.4

[90.1-92.6]

84.0

[81.9-86]

**

I.b Acute myeloid leukemias

66.1

[58.9-72.4]

66.9

[61.9-71.3]

80.8

[75.6-85.1]

67.6

[62.4-72.3]

**

II. Lymphomas and reticuloendothelial neoplasms

92.9

[59.1-99.0]

92.5

[89.3-94.8]

94.4

[92.7-95.7]

94.7

[93.5-95.6]

 

II.a Hodgkin lymphomas

-

-

100.0

-

98.6

[96.3-99.5]

97.4

[96.3-98.2]

 

II.b Non-Hodgkin lymphomas (except Burkitt lymphomas)

90.9

[50.8-98.7]

86.4

[79.9-90.9]

89.9

[85.9-92.7]

90.3

[87.2-92.7]

 

II.c Burkitt lymphomas

100.0

-

96.0

[91.8-98.1]

95.1

[92.3-96.9]

90.4

[85.6-93.6]

 

III. CNS and miscellaneous intracranial and intraspinal neoplasms

62.7

[58.2-66.9]

72.9

[71-74.6]

72.4

[70.6-74.2]

81.4

[79.7-83.1]

**

III.a Ependymomas and choroid plexus tumors

70.5

[60.3-78.5]

67.9

[62.1-72.9]

79.9

[72.2-85.6]

86.9

[79.7-91.6]

**

III.b Astrocytomas

82.5

[75.1-87.8]

94.3

[92.6-95.5]

82.9

[80.3-85.3]

82.5

[79.4-85.1]

**

III.c Intracranial and intraspinal embryonal tumors

26.1

[18.7-34.1]

38.1

[33.8-42.3]

69.1

[64.6-73.1]

79.1

[73.3-83.8]

**

III.d Other gliomas

67.2

[50.3-79.5]

44.5

[38.2-50.5]

26.2

[22.0-30.6]

47.0

[41.3-52.6]

**

III.e Other specified intracranial and intraspinal neoplasms

84.2

[71.9-91.5]

94.2

[90.5-96.5]

95.6

[93.2-97.1]

96.7

[94.9-97.8]

**

IV. Neuroblastomas and other peripheral nervous cell tumors

90.7

[88.6-92.4]

67.2

[64.3-70.0]

66.1

[59.7-71.8]

71.4

[60.0-80.0]

**

IV.a Neuroblastomas and ganglioneuroblastomas

90.7

[88.7-92.5]

67.1

[64.2-69.9]

66.2

[59.7-71.9]

62.8

[49.4-73.6]

**

V. Retinoblastomas

99.5

[97.9-99.9]

99.0

[97.5-99.6]

100.0

-

100.0

-

 

VI. Renal tumors

88.3

[83.5-91.9]

94.3

[92.7-95.6]

93.2

[89.8-95.5]

81.9

[70.3-89.3]

**

VI.a Nephroblastomas and other nonepithelial renal tumors

88.3

[83.5-91.9]

94.3

[92.7-95.6]

93.3

[89.8-95.6]

85.0

[69.6-93.0]

**

VII. Hepatic tumors

89.9

[80.8-94.8]

87.3

[80.8-91.7]

74.4

[55.0-86.4]

62.4

[45.5-75.4]

**

VII.a Hepatoblastomas

89.7

[80.5-94.7]

87.5

[80.8-91.9]

74.6

[51.9-87.7]

44.4

[13.6-71.9]

**

VIII. Malignant bone tumors

85.7

[33.4-97.9]

74.2

[63.2-82.4]

75.2

[70.5-79.2]

73.6

[70.5-76.4]

 

VIII.a Osteosarcomas

100.0

-

57.1

[28.4-78.0]

71.1

[63.4-77.4]

71.7

[67.2-75.7]

 

VIII.c Ewing tumors and related bone sarcomas

80.0

[20.4-96.9]

78.4

[65.6-86.9]

77.4

[70.7-82.7]

73.9

[68.9-78.2]

 

IX. Soft tissue and other extraosseous sarcomas

69.8

[62.9-75.8]

75.2

[71.4-78.5]

75.3

[71.2-78.9]

68.2

[64.1-72.0]

**

IX.a Rhabdomyosarcomas

84.6

[73.3-91.4]

76.3

[71.9-80.0]

72.9

[67.5-77.6]

60.8

[53.1-67.6]

**

IX.b Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms

88.7

[76.5-94.7]

91.7

[53.9-98.8]

82.6

[60.0-93.1]

67.2

[50.7-79.3]

 

IX.d Other specified soft tissue sarcomas

39.0

[26.7-51.1]

72.7

[63.0-80.3]

79.2

[71.3-85.2]

72.6

[66.8-77.6]

**

IX.e Unspecified soft tissue sarcomas

56.3

[29.5-76.2]

49.7

[27.4-68.5]

74.5

[56.4-85.9]

71.0

[57.8-80.7]

 

X. Germ-cell tumors, trophoblastic tumors, and neoplasms of gonads

91.3

[87.1-94.2]

96.3

[92.7-98.1]

96.9

[92.6-98.7]

93.5

[90.7-95.4]

*

X.a Intracranial and intraspinal germ cell tumors

91.6

[76.1-97.2]

93.4

[84.8-97.2]

95.6

[88.6-98.3]

94.5

[90.3-96.9]

 

X.b Malignant extracranial and extragonadal germ cell tumors

89.1

[83.5-92.9]

96.2

[88.6-98.8]

100.0

-

85.7

[66.1-94.4]

 

X.c Malignant gonadal germ cell tumors

100.0

-

100.0

-

100.0

-

96.0

[92.1-98.0]

 

XI. Other malignant epithelial neoplasms and malignant melanomas

96.9

[79.8-99.6]

87.5

[79.0-92.7]

93.1

[88.6-95.8]

94.0

[91.8-95.6]

 

XI.b Thyroid carcinomas

100.0

-

100.0

-

98.8

[91.5-99.8]

98.9

[96.6-99.6]

 

XI.d Malignant melanomas

100.0

-

81.0

[62.5-91.0]

89.3

[76.2-95.4]

88.3

[79.9-93.4]

 

XII. Other and unspecified malignant neoplasms

100.0

-

76.5

[58.4-87.5]

85.7

[33.4-97.9]

58.6

[26.7-80.6]

 

All cancers (excluding Langherhans cell histiocytosis)

81.3

[79.9-82.7]

83.3

[82.6-84.1]

82.6

[81.7-83.4]

83.7

[82.9-84.5]

**

Langherhans cell histiocytosis

87.2

[73.8-94.1]

96.4

[86.2-99.1]

100.0

-

100.0

-

 

All cancers (including Langherhans cell histiocytosis)

81.4

[80.0-82.8]

83.4

[82.7-84.1]

82.6

[81.7-83.4]

83.8

[82.9-84.6]

**

                   

** pvalue <0.01; * pvalue < 0.05

                 
                   
                   

Overall survival rates (OS) of childhood cancer in mainland France over 2000-2016, by diagnostic groups and sub.

             
               
 

Taux de survie (IC95%)

Diagnostic groups and subgroups

N

1y-OS

2y-OS

5y-OS

I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases

8503

94.1

[93.6-94.6]

90.4

[89.7-91.0]

86.1

[85.3-86.8]

I.a Lymphoid leukemias

6678

96.4

[95.9-96.8]

93.8

[93.1-94.3]

90.0

[89.3-90.7]

I.b Acute myeloid leukemias

1231

84.6

[82.5-86.5]

76.6

[74.1-78.9]

70.2

[67.5-72.7]

II. Lymphomas and reticuloendothelial neoplasms

3258

96.9

[96.3-97.5]

95.4

[94.6-96.1]

94.3

[93.4-95.1]

II.a Hodgkin lymphomas

1480

99.6

[99.1-99.8]

98.8

[98.0-99.2]

97.7

[96.8-98.4]

II.b Non-Hodgkin lymphomas (except Burkitt lymphomas)

983

94.6

[93.0-95.9]

91.4

[89.4-93.0]

89.5

[87.4-91.3]

II.c Burkitt lymphomas

788

94.9

[93.1-96.3]

94.3

[92.4-95.7]

94.0

[92.0-95.4]

III. CNS and miscellaneous intracranial and intraspinal neoplasms

7500

85.7

[84.9-86.5]

79.3

[78.4-80.2]

74.4

[73.4-75.4]

III.a Ependymomas and choroid plexus tumors

709

91.4

[89.0-93.2]

85.9

[83.1-88.2]

74.6

[71.1-77.8]

III.b Astrocytomas

2798

92.7

[91.7-93.6]

88.8

[87.6-89.9]

87.0

[85.6-88.2]

III.c Intracranial and intraspinal embryonal tumors

1422

75.4

[73.1-77.6]

66.0

[63.4-68.4]

55.7

[53.0-58.4]

III.d Other gliomas

1017

62.3

[59.2-65.2]

44.8

[41.7-47.8]

38.7

[35.6-41.7]

III.e Other specified intracranial and intraspinal neoplasms

1436

97.7

[96.8-98.4]

96.5

[95.4-97.4]

95.3

[94.1-96.3]

IV. Neuroblastomas and other peripheral nervous cell tumors

2404

92.0

[90.8-93.0]

85.6

[84.1-86.9]

76.4

[74.6-78.1]

IV.a Neuroblastomas and ganglioneuroblastomas

2372

92.0

[90.8-93.0]

85.5

[84.0-86.9]

76.2

[74.4-77.9]

V. Retinoblastomas

849

99.5

[98.7-99.8]

99.5

[98.7-99.8]

99.3

[98.4-99.7]

VI. Renal tumors

1637

96.8

[95.8-97.6]

94.5

[93.3-95.5]

92.7

[91.3-93.9]

VI.a Nephroblastomas and other nonepithelial renal tumors

1583

97.0

[96.0-97.7]

94.8

[93.6-95.8]

93.0

[91.6-94.2]

VII. Hepatic tumors

304

90.4

[86.5-93.3]

86.5

[82.1-89.8]

83.1

[78.4-87.0]

VII.a Hepatoblastomas

256

91.0

[86.8-93.9]

86.3

[81.4-90.0]

85.4

[80.5-89.2]

VIII. Malignant bone tumors

1422

94.4

[93.1-95.5]

87.0

[85.1-88.6]

74.1

[71.7-76.4]

VIII.a Osteosarcomas

660

93.0

[90.8-94.7]

85.7

[82.7-88.1]

71.3

[67.5-74.7]

VIII.c Ewing tumors and related bone sarcomas

657

95.9

[94.1-97.2]

87.9

[85.2-90.2]

75.4

[71.8-78.7]

IX. Soft tissue and other extraosseous sarcomas

1882

90.2

[88.7-91.4]

81.8

[80.0-83.5]

72.5

[70.4-74.6]

IX.a Rhabdomyosarcomas

1019

92.5

[90.7-94.0]

83.5

[81.0-85.6]

73.0

[70.1-75.7]

IX.b Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms

139

92.8

[87.0-96.1]

87.1

[80.2-91.6]

81.2

[73.3-86.9]

IX.d Other specified soft tissue sarcomas

579

86.2

[83.1-88.7]

79.4

[75.9-82.5]

70.9

[66.9-74.5]

IX.e Unspecified soft tissue sarcomas

141

86.5

[79.7-91.2]

74.4

[66.4-80.8]

66.8

[58.1-74.1]

X. Germ-cell tumors, trophoblastic tumors, and neoplasms of gonads

1113

96.5

[95.2-97.4]

95.0

[93.5-96.1]

94.1

[92.5-95.3]

X.a Intracranial and intraspinal germ cell tumors

423

96.6

[94.4-98.0]

95.1

[92.6-96.8]

94.3

[91.6-96.2]

X.b Malignant extracranial and extragonadal germ cell tumors

291

93.5

[90.0-95.8]

92.1

[88.3-94.7]

90.9

[86.9-93.7]

X.c Malignant gonadal germ cell tumors

369

98.9

[97.1-99.6]

98.3

[96.4-99.3]

97.8

[95.6-98.9]

XI. Other malignant epithelial neoplasms and malignant melanomas

1024

96.5

[95.1-97.5]

95.0

[93.4-96.2]

93.3

[91.5-94.7]

XI.b Thyroid carcinomas

411

99.3

[97.7-99.8]

99.3

[97.7-99.8]

99.0

[97.3-99.6]

XI.d Malignant melanomas

186

92.3

[87.4-95.4]

91.2

[86.0-94.5]

87.4

[81.5-91.5]

XII. Other and unspecified malignant neoplasms

70

86.6

[75.8-92.8]

80.5

[68.9-88.2]

78.9

[67.0-86.9]

All cancers (excluding Langherhans cell histiocytosis)

29966

92.3

[92.0-92.6]

87.8

[87.4-88.2]

83.1

[82.6-83.5]

Langherhans cell histiocytosis

118

93.9

[87.7-97.1]

93.1

[86.6-96.5]

93.1

[86.6-96.5]

All cancers (including Langherhans cell histiocytosis)

30084

92.3

[92.0-92.6]

87.8

[87.4-88.2]

83.1

[82.7-83.5]

               
               
               

Temporal variations in the incidence rate of childhood cancer in mainland France, 2000-2016.

       
         
         

Diagnostic groups and subgroups

N

AAPC (%)

CI95%

p

I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases

8 503

0.1

[-0.3;0.6]

0.51

I.a Lymphoid leukemias

6 678

0.3

[-0.2;0.8]

0.18

I.b Acute myeloid leukemias

1 231

-0.5

[-1.6;0.7]

0.43

II. Lymphomas and reticuloendothelial neoplasms

3 258

-0.4

[-1.1;0.3]

0.22

II.a Hodgkin lymphomas

1 480

0.5

[-0.5;1.6]

0.34

II.b Non-Hodgkin lymphomas (except Burkitt lymphomas)

983

-0.7

[-2.0;0.6]

0.29

II.c Burkitt lymphomas

788

-1.9

[-3.3;-0.5]

< 0.01

III. CNS and miscellaneous intracranial and intraspinal neoplasms

7 500

1.2

[0.7;1.7]

< 0.01

III.a Ependymomas and choroid plexus tumors

709

0.5

[-1.0;2.0]

0.52

III.b Astrocytomas

2 798

1.3

[0.5;2.0]

< 0.01

III.c Intracranial and intraspinal embryonal tumors

1 422

0.0

[-1.1;1.0]

0.96

III.d Other gliomas

1 017

0.5

[-0.7;1.8]

0.40

III.e Other specified intracranial and intraspinal neoplasms

1 436

3.2

[2.1;4.3]

< 0.01

IV. Neuroblastomas and other peripheral nervous cell tumors

2 404

-0.5

[-1.3;0.3]

0.20

IV.a Neuroblastomas and ganglioneuroblastomas

2 372

-0.5

[-1.4;0.3]

0.19

V. Retinoblastomas

849

-0.4

[-1.8;1.0]

0.57

VI. Renal tumors

1 637

-0.5

[-1.5;0.5]

0.29

VI.a Nephroblastomas and other nonepithelial renal tumors

1 583

-0.4

[-1.4;0.6]

0.41

VII. Hepatic tumors

304

1.8

[-0.5;4.2]

0.12

VII.a Hepatoblastomas

256

2.0

[-0.6;4.6]

0.13

VIII. Malignant bone tumors

1 422

0.4

[-0.7;1.5]

0.47

VIII.a Osteosarcomas

660

-0.2

[-1.8;1.3]

0.78

VIII.c Ewing tumors and related bone sarcomas

657

1.6

[0.0;3.2]

0.05

IX. Soft tissue and other extraosseous sarcomas

1 882

-0.1

[-1.1;0.8]

0.76

IX.a Rhabdomyosarcomas

1 019

0.0

[-1.3;1.2]

0.94

IX.b Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms

139

0.7

[-2.6;4.2]

0.68

IX.d Other specified soft tissue sarcomas

579

-0.5

[-2.2;1.1]

0.52

IX.e Unspecified soft tissue sarcomas

141

0.5

[-2.8;4.0]

0.76

X. Germ-cell tumors, trophoblastic tumors, and neoplasms of gonads

1 113

-0.9

[-2.1;0.2]

0.12

X.a Intracranial and intraspinal germ cell tumors

423

0.0

[-1.9;2.0]

0.99

X.b Malignant extracranial and extragonadal germ cell tumors

291

-2.1

[-4.4;0.2]

0.08

X.c Malignant gonadal germ cell tumors

369

-1.3

[-3.3;0.8]

0.21

XI. Other malignant epithelial neoplasms and malignant melanomas

1 024

1.4

[0.1;2.7]

0.03

XI.b Thyroid carcinomas

411

-1.3

[-3.3;0.6]

0.19

XI.d Malignant melanomas

186

-1.2

[-4.0;1.8]

0.44

XII. Other and unspecified malignant neoplasms

70

4.8

[-0.2;10.0]

0.06

All cancers (excluding Langherhans cell histiocytosis)

29 966

0.3

[0.0;0.5]

0.03

Langherhans cell histiocytosis

118

-1.0

[-4.6;2.7]

0.6

All cancers (including Langherhans cell histiocytosis)

30 084

0.3

[0.0;0.5]

0.03

AAPC: average annual percent change in incidence rate (estimated by Poisson regression model)

       
         
         

Annual number of cases (N), age specific annual incidence rates (IR), mainland France 2012-2016.

               
                 
 

< 1 year

1-4 years

5-9 years

10-14 years

Diagnostic groups and subgroups

N

IR

N

IR

N

IR

N

IR

I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases

30

40.1

217

70.4

156

39.3

116

29.2

I.a Lymphoid leukemias

12

16.1

187

60.6

130

32.6

85

21.3

I.b Acute myeloid leukemias

12

16.1

23

7.4

19

4.7

21

5.3

II. Lymphomas and reticuloendothelial neoplasms

1

1.3

24

7.7

57

14.3

109

27.5

II.a Hodgkin lymphomas

0

0.0

3

1.0

18

4.4

73

18.4

II.b Non-Hodgkin lymphomas (except Burkitt lymphomas)

1

0.8

10

3.4

19

4.8

26

6.6

II.c Burkitt lymphomas

0

0.0

10

3.4

20

5.1

10

2.5

III. CNS and miscellaneous intracranial and intraspinal neoplasms

28

37.4

157

51.0

157

39.4

138

34.9

III.a Ependymomas and choroid plexus tumors

6

7.5

22

7.0

10

2.5

7

1.9

III.b Astrocytomas

8

11.3

72

23.3

56

14.2

44

11.0

III.c Intracranial and intraspinal embryonal tumors

7

8.9

30

9.6

34

8.7

15

3.9

III.d Other gliomas

2

3.0

14

4.7

27

6.8

19

4.7

III.e Other specified intracranial and intraspinal neoplasms

4

5.9

16

5.3

27

6.8

51

13.0

IV. Neuroblastomas and other peripheral nervous cell tumors

54

72.3

65

20.9

17

4.2

5

1.2

IV.a Neuroblastomas and ganglioneuroblastomas

54

72.3

64

20.7

17

4.2

4

0.9

V. Retinoblastomas

22

29.3

27

8.8

2

0.5

0

0.1

VI. Renal tumors

13

17.7

57

18.4

20

5.0

5

1.2

VI.a Nephroblastomas and other nonepithelial renal tumors

13

17.7

57

18.4

19

4.8

3

0.8

VII. Hepatic tumors

6

7.5

10

3.1

2

0.6

2

0.6

VII.a Hepatoblastomas

5

7.3

9

2.9

2

0.6

0

0.1

VIII. Malignant bone tumors

1

1.1

6

1.9

22

5.5

62

15.5

VIII.a Osteosarcomas

0

0.0

1

0.3

9

2.3

30

7.7

VIII.c Ewing tumors and related bone sarcomas

1

0.8

4

1.4

11

2.7

28

7.1

IX. Soft tissue and other extraosseous sarcomas

12

16.4

36

11.6

30

7.5

32

8.0

IX.a Rhabdomyosarcomas

5

7.0

27

8.6

18

4.5

10

2.5

IX.b Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms

2

3.2

1

0.3

2

0.6

3

0.8

IX.d Other specified soft tissue sarcomas

3

4.6

7

2.1

7

1.9

15

3.8

IX.e Unspecified soft tissue sarcomas

1

1.6

2

0.5

2

0.6

4

0.9

X. Germ-cell tumors, trophoblastic tumors, and neoplasms of gonads

12

15.9

13

4.2

12

3.0

28

7.1

X.a Intracranial and intraspinal germ cell tumors

1

1.9

5

1.6

8

2.0

13

3.2

X.b Malignant extracranial and extragonadal germ cell tumors

9

11.6

5

1.6

0

0.1

1

0.2

X.c Malignant gonadal germ cell tumors

2

2.2

3

1.0

4

1.0

13

3.2

XI. Other malignant epithelial neoplasms and malignant melanomas

2

2.4

7

2.4

13

3.3

50

12.6

XI.b Thyroid carcinomas

0

0.5

2

0.5

3

0.8

17

4.2

XI.d Malignant melanomas

0

0.0

3

0.9

3

0.7

5

1.3

XII. Other and unspecified malignant neoplasms

2

2.2

3

0.9

0

0.1

1

0.2

All cancers (excluding Langherhans cell histiocytosis)

181

243.5

622

201.3

488

122.8

547

138.0

Langherhans cell histiocytosis

2

2.2

3

1.0

0

0.1

1

0.2

All cancers (including Langherhans cell histiocytosis)

183

245.7

625

202.3

488

122.9

548

138.2

Annual number of cases (N), crude, age standardised and cumulative incidence rate of childhood cancer, and sex ratio (mainland France, 2012-2016).

         
           
   

Incidence rate (/million)

 

Diagnostic groups and subgroups

N

Crude

ASR

cumulative

Sex_ratio

I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases

519

44.1

46.1

664.0

1.2

I.a Lymphoid leukemias

413

35.1

36.7

527.9

1.2

I.b Acute myeloid leukemias

75

6.3

6.6

95.7

1.0

I.c Chronic myeloproliferative diseases

10

0.9

0.8

13.5

1.2

I.d Myelodysplastic syndromes and other myeloproliferative diseases

14

1.2

1.3

18.4

1.7

I.e Unspecified and other specified leukemias

6

0.5

0.5

8.0

1.5

II. Lymphomas and reticuloendothelial neoplasms

191

16.2

15.1

241.1

1.9

II.a Hodgkin lymphomas

93

7.9

7.1

118.0

1.3

II.b Non-Hodgkin lymphomas (except Burkitt lymphomas)

56

4.8

4.6

71.4

2.0

II.c Burkitt lymphomas

41

3.5

3.4

51.6

4.0

II.d Miscellaneous lymphoreticular neoplasms

0

0.0

0.0

0.5

-

II.e Unspecified lymphomas

0

0.0

0.0

0.5

-

III. CNS and miscellaneous intracranial and intraspinal neoplasms

480

40.8

41.5

612.7

1.2

III.a Ependymomas and choroid plexus tumors

44

3.8

4.1

57.5

1.3

III.b Astrocytomas

181

15.3

15.9

230.5

1.0

III.c Intracranial and intraspinal embryonal tumors

86

7.3

7.6

110.3

1.5

III.d Other gliomas

62

5.3

5.2

79.3

1.1

III.e Other specified intracranial and intraspinal neoplasms

99

8.4

8.1

126.1

1.2

III.f Unspecified intracranial and intraspinal neoplasms

7

0.6

0.7

9.7

0.9

IV. Neuroblastomas and other peripheral nervous cell tumors

140

11.9

13.8

182.9

1.1

IV.a Neuroblastomas and ganglioneuroblastomas

138

11.7

13.6

180.6

1.1

IV.b Other peripheral nervous cell tumors

2

0.2

0.2

2.8

0.8

V. Retinoblastomas

51

4.4

5.2

67.5

1.1

VI. Renal tumors

95

8.1

9.0

122.3

0.8

VI.a Nephroblastomas and other nonepithelial renal tumors

92

7.8

8.8

119.3

0.8

VI.b Renal carcinomas

3

0.2

0.2

3.5

0.4

VI.c Unspecified malignant renal tumors

0

0.0

0.0

0.0

-

VII. Hepatic tumors

20

1.7

1.9

25.9

1.9

VII.a Hepatoblastomas

17

1.5

1.7

22.4

2.1

VII.b Hepatic carcinomas

3

0.2

0.2

3.3

1.5

VII.c Unspecified malignant hepatic tumors

0

0.0

0.0

0.3

0.0

VIII. Malignant bone tumors

90

7.6

6.9

113.7

1.1

VIII.a Osteosarcomas

40

3.4

3.1

51.2

0.9

VIII.b Chondrosarcomas

2

0.1

0.1

2.3

1.0

VIII.c Ewing tumors and related bone sarcomas

44

3.7

3.4

55.4

1.4

VIII.d Other specified malignant bone tumors

4

0.3

0.3

4.9

1.0

VIII.e Unspecified malignant bone tumors

1

0.1

0.1

1.3

2.9

IX. Soft tissue and other extraosseous sarcomas

110

9.3

9.6

140.3

1.2

IX.a Rhabdomyosarcomas

60

5.1

5.4

76.4

1.3

IX.b Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms

9

0.7

0.8

11.4

0.9

IX.c Kaposi sarcomas

0

0.0

0.0

0.0

-

IX.d Other specified soft tissue sarcomas

33

2.8

2.7

41.5

1.1

IX.e Unspecified soft tissue sarcomas

9

0.7

0.7

11.1

1.2

X. Germ-cell tumors, trophoblastic tumors, and neoplasms of gonads

65

5.5

5.6

83.2

0.9

X.a Intracranial and intraspinal germ cell tumors

27

2.3

2.2

34.3

2.6

X.b Malignant extracranial and extragonadal germ cell tumors

15

1.2

1.5

19.5

0.6

X.c Malignant gonadal germ cell tumors

21

1.8

1.7

27.2

0.4

X.d Gonadal carcinomas

1

0.1

0.1

1.0

0.0

X.e Other and unspecified malignant gonadal tumors

1

0.1

0.1

1.8

0.2

XI. Other malignant epithelial neoplasms and malignant melanomas

72

6.1

5.6

91.5

0.7

XI.a Adrenocortical carcinomas

5

0.5

0.5

7.2

0.9

XI.b Thyroid carcinomas

22

1.9

1.7

27.5

0.5

XI.c Nasopharyngeal carcinomas

4

0.4

0.3

5.5

1.9

XI.d Malignant melanomas

11

0.9

0.9

13.6

0.7

XI.e Skin carcinomas

3

0.3

0.3

4.3

1.1

XI.f Other and unspecified carcinomas

26

2.2

2.0

33.4

0.6

XII. Other and unspecified malignant neoplasms

5

0.5

0.5

7.3

0.8

XII.a Other specified malignant tumors

5

0.4

0.5

6.4

0.7

XII.b Other unspecified malignant tumors

1

0.1

0.1

1.4

1.9

All cancers (excluding Langherhans cell histiocytosis)

1838

156.2

160.8

2349.9

1.2

Langherhans cell histiocytosis

5

0.5

0.6

7.7

1.0

All cancers (including Langherhans cell histiocytosis)

1843

156.6

161.4

2357.6

1.2

           
           
           
Plusieurs dizaines de milliers de personnes ont eu un cancer au cours de leur enfance. Ce cancer et son traitement ont pu laisser des séquelles à l’origine de handicaps et d’altérations de la qualité de vie, les traitements sont susceptibles d’induire des effets indésirables à long terme qu’il faut identifier et dépister. Pour améliorer la connaissance de ces effets et contribuer à la surveillance systématique de cette population, l’équipe a mis en place la cohorte COHOPER qui suit passivement les patients par les bases médico-administratives et suit par questionnaire les patients qui acceptent de répondre à cette sollicitation.

logo cohoper sous titre HD

 

 

ABOUT US

Le Registre National des Cancers de l'Enfant (RNCE) est composé du Registre National des Hémopathies malignes de l'Enfant (RNHE), implanté à l'hôpital Paul Brousse, à Villejuif, et du Registre National des Tumeurs Solides de l'Enfant (RNTSE), implanté au CHRU de Nancy.

L'équipe

 

Direction

 
Jacqueline CLAVEL
Jacqueline CLAVELEquipe Villejuif
MD, PHD Epidémiologiste Directeur du RNHE
Brigitte LACOUR
Brigitte LACOUREquipe Nancy
MD Epidémiologiste Directeur du RNTSE
 
 

Administration

 
Evelyne PRZYBILSKI
Evelyne PRZYBILSKIEquipe Villejuif
Secrétariat - Gestion équipe EPICEA
Françoise PIRON
Françoise PIRONEquipe Nancy
Secrétariat - Gestion équipe CHRU
 
 

Epidémiologistes

 
Jacqueline CLAVEL
Jacqueline CLAVELEquipe Villejuif
MD, PHD Epidémiologiste Directeur du RNHE
Brigitte LACOUR
Brigitte LACOUREquipe Nancy
MD Epidémiologiste Directeur du RNTSE
Denis HÉMON
Denis HÉMONEquipe Villejuif
PHD Epidémiologiste
 
Emmanuel DESANDES
Emmanuel DESANDESEquipe Nancy
MD Epidémiologiste
Pauline BROSSELIN
Pauline BROSSELINEquipe Villejuif
MD, MSc, Epidémiologiste
Helen BAILEY
Helen BAILEYEquipe Villejuif
MPH, PHD Epidémiologiste
Audrey BONAVENTURE
Audrey BONAVENTUREEquipe Villejuif
MD, PHD, Epidémiologiste
Claire POULALHON
Claire POULALHONEquipe Villejuif
MD Epidémiologiste
 

Statisticiens

 
Stéphanie GOUJON
Stéphanie GOUJONEquipe Villejuif
Statisticienne du RNCE
Hélène BAUER
Hélène BAUEREquipe Villejuif
Statisticienne
Kadiatou KABA
Kadiatou KABAEquipe Villejuif
Statisticienne GEOCAP
 

Chefs de projet RNCE

 
Laure FAURE
Laure FAUREEquipe Villejuif
Coordinatrice du recueil des données du RNHE
Sandra GUISSOU
Sandra GUISSOUEquipe Nancy
Coordinatrice du recueil des données du RNTSE
 
 

Techniciens RNCE

 
Karine FEUERSTOSE
Karine FEUERSTOSEEquipe Nancy
Enregistrement des données du RNTSE
Hanna HANNA
Hanna HANNAEquipe Villejuif
Recueil et vérification des données du RNCE
 
 

Chefs de projet Plateforme

 
Latifa IDBRIK
Latifa IDBRIKEquipe Villejuif
Chef de projet de HOPE-EPI, encadrement du recueil COHOPER hémopathies malignes
Lucie VIGNON
Lucie VIGNONEquipe Villejuif
Chef de projet COHOPER, encadrement du recueil COHOPER tumeurs solides
 
 

Data managers

 
Sofiène BEN SALHA
Sofiène BEN SALHAEquipe Villejuif
Data manager spécialisé BIOCAP
Nicolas SIMON
Nicolas SIMONEquipe Villejuif
Data manager spécialisé COHOPER
Florian PONTIN
Florian PONTINEquipe Villejuif
Data manager
 
 
 

Doctorants

 
Justine BERLIVET
Justine BERLIVETEquipe Villejuif
Claire POULALHON
Claire POULALHONEquipe Villejuif
MD Epidémiologiste
Paula RIOS
Paula RIOSEquipe Villejuif
 
Nicolas VIDART
Nicolas VIDARTEquipe Villejuif
Sophie BAMOUNI
Sophie BAMOUNIEquipe Villejuif
 
 
 
 

RNCE newsletter icon bleuClick here to read our newsletter

 

Subscribe our newsletter

Abonnez-vous à notre newsletter

Villejuif

INSERM
UMRS1153 Equipe 7
Bâtiment 15/16
16 avenue Paul Vaillant Couturier
94807 Villejuif Cedex

+33 (0)1 45 59 50 37
rnhe@inserm.fr

Nancy

Faculté de Médecine
BP 20199
9 avenue de la Forêt de Haye
54505 Vandoeuvre les Nancy Cedex

+33 (0)3 72 74 63 26
rntse@inserm.fr